Clopidogrel Tablet
Product Images NDC 42543-713

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 42543-713). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Vensun Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clopidogrel Tablets 300 mg Bottle (Clopidogrel 300mg 30tabs)

Label for Clopidogrel Tablets USP 300 mg in a 30-tablet package. The label states each tablet contains clopidogrel bisulfate equivalent to 300 mg of clopidogrel base. It includes storage instructions, a barcode, and manufacturer information: Vensun Pharmaceuticals, Inc. and ScieGen Pharmaceuticals, Inc. The label also highlights dispensing the medication guide to patients and displays the NDC 42543-714-30.*

FDA Label Image

Clopidogrel Tablets 75 mg Bottle (Clopidogrel 75mg 30tabs)

Label for Clopidogrel Tablets, USP 75 mg oral tablets, with package of 30 tablets. The label includes directions for pharmacists to dispense the accompanying medication guide, storage instructions, and manufacturer information: Vensun Pharmaceuticals, Inc., and ScieGen Pharmaceuticals, Inc. A barcode and the NDC 42543-713-30 are also present.*

FDA Label Image

Figure1 (Clopidogrel Fig)

A figure showing the effect of multiple doses of Clopidogrel 75 mg alone or with co-administered proton pump inhibitors (PPIs) on exposure to clopidogrel active metabolite. The chart displays the mean effect and 90% confidence intervals of PPIs (Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, Omeprazole 80 mg) on the active metabolite AUC, illustrating the change relative to clopidogrel administered alone.*

FDA Label Image

Figure3 (Clopidogrel Fig2)

A line graph depicting cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up comparing clopidogrel (+ aspirin) versus placebo (+ aspirin). The graph shows lower event rates with clopidogrel treatment, with statistical significance indicated (P=0.00009). Additional standard therapies were used as appropriate.*

FDA Label Image

Figure3 (Clopidogrel Fig3)

A pair of forest plots displaying hazard ratios with 95% confidence intervals for Clopidogrel versus placebo. The plots show subgroup analysis based on demographics (age, gender, race) and clinical factors (diabetes, previous MI, stroke) in the first plot, and medication use (heparin/LMWH, aspirin dosage, beta-blocker, ACE inhibitor) in the second plot. The x-axes range from 0.3 to 1.4 hazard ratio and compare favorability toward Clopidogrel or placebo.*

FDA Label Image

Figure4 (Clopidogrel Fig4)

A cumulative event rate graph showing the percentage of deaths before first discharge over 28 days since randomization in the COMMIT study. It compares clopidogrel and placebo groups, indicating 8.1% deaths with placebo and 7.5% with clopidogrel, noting a 7% proportional risk reduction (p=0.03). All patients received aspirin.*

FDA Label Image

Figure5 (Clopidogrel Fig5)

A line chart showing the percentage of patients with death, re-infarction, or stroke before first discharge over 28 days since randomization. It compares outcomes between a placebo group and a clopidogrel group, indicating a slightly lower event percentage in the clopidogrel group, with a noted 9% proportional risk reduction (p=0.002).*

FDA Label Image

Figure6 (Clopidogrel Fig6)

A forest plot chart showing the effects of adding clopidogrel to aspirin on combined primary endpoints in various subgroups for the COMMIT study. The subgroups include gender, age at entry, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent given. The chart presents odds ratios with confidence intervals comparing clopidogrel versus placebo.*

FDA Label Image

Figure7 (Clopidogrel Fig7)

A line graph titled 'Fatal or Non-Fatal Vascular Events' depicting cumulative event rates (%) over 36 months of follow-up. It compares two groups labeled 'Aspirin' and 'Clopidogrel,' showing cumulative event rates increasing over time, with 'Clopidogrel' generally having a lower rate. A p-value of 0.045 is displayed, indicating statistical comparison between groups.*

FDA Label Image

Figure8 (Clopidogrel Fig8)

A forest plot figure titled 'Hazard Ratio and 95% CI by Baseline Subgroups in the CAPRIE Study,' comparing Clopidogrel and Aspirin across qualifying conditions Stroke, MI, PAD, and Overall. The x-axis shows hazard ratios from 0.6 to 1.3, with markers indicating the point estimates and confidence intervals for each subgroup, visually depicting relative favorability between Clopidogrel and Aspirin.*

FDA Label Image

Structure (Clopidogrel Str)

Chemical structure of clopidogrel as shown in this diagram includes a bicyclic ring system with sulfur, a chlorine-substituted phenyl ring, a methoxycarbonyl group, and an associated sulfuric acid (H2SO4) molecule.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.